STOCK TITAN

374Water director buys $25K convertible note

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

374Water Inc. (SCWO) director James Pawloski reported acquiring a $50,000-principal 10% secured convertible note and a warrant for 10,000 common shares on March 11, 2026, in a private placement. The note was purchased at 100% of principal, and the warrant was issued with it for no separate consideration.

On May 29, 2026, the issuer amended those securities: the note’s conversion price changed from $5.00 to $3.00 per share, and the warrant’s exercise price from $7.50 to $4.50, while warrant coverage increased from 10,000 to 16,667 shares. The original instruments were reported as deemed canceled and the amended instruments acquired; no additional consideration was paid. On November 2, 2026, Pawloski acquired a $25,000-principal note and a warrant for 8,333 shares.

The Notes bear 10% annual interest, and the Warrants are exercisable for cash only. On September 30, 2026, $2,780.82 of deferred interest was added to the March note’s principal, but that amount is excluded from the principal and underlying-share figures reported. No Rule 10b5-1 plan is reported.

Insider Pawloski James
Role Director
Type Security Shares Price Value
Grant/Award 10% Secured Convertible Note F1, F2, F3 25,000 $25,000.00 as filed --
Grant/Award Warrant (right to buy) F4, F2 8,333 $0.00 $0.00
Disposition 10% Secured Convertible Note F5, F3 50,000 -- --
Grant/Award 10% Secured Convertible Note F5, F3 50,000 -- --
Disposition Warrant (right to buy) F5 10,000 -- --
Grant/Award Warrant (right to buy) F5 16,667 -- --
Grant/Award 10% Secured Convertible Note F1, F2 50,000 $50,000.00 as filed --
Grant/Award Warrant (right to buy) F4, F2 10,000 $0.00 $0.00
  • 10% Secured Convertible Note, Nov 2, 2026. Price shown as filed: $25,000.00 per share is far above the $2.54 close on Nov 2, 2026, so no transaction value is shown.
  • 10% Secured Convertible Note, Mar 11, 2026. Price shown as filed: $50,000.00 per share is far above the $2.60 close on Mar 11, 2026, so no transaction value is shown.
Holdings After Transaction: 10% Secured Convertible Note — 75,000 (Direct); Warrant (right to buy) — 25,000 warrants (Direct)
Footnotes (5)
  1. F1. The reporting person acquired the Issuer's 10% Secured Convertible Notes (the "Notes") and the related common stock purchase warrants (the "Warrants") from the Issuer in a private placement. The reporting person's participation was approved in advance by the Issuer's Board of Directors, and the acquisition is exempt under Rule 16b-3(d). The Notes are reported by principal amount.
  2. F2. The Notes were purchased at 100% of their principal amount. The Warrants were issued together with the Notes for no separate consideration.
  3. F3. The Notes bear interest at 10% per annum and are convertible, at the holder's option, into common stock at any time before the close of business on the third scheduled trading day preceding the maturity date, which is three years from the date of issuance. The number of underlying shares is the principal amount divided by the conversion price, rounded to the nearest whole share, and excludes accrued and unpaid interest, which is also convertible at the conversion price. On September 30, 2026, $2,780.82 of deferred interest was added to the principal amount of the Note issued on March 11, 2026; that amount is not included in the principal amount or underlying shares reported above.
  4. F4. The Warrants are exercisable for cash only, beginning on the date of issuance and expiring three years thereafter. The number of Warrant shares equals 100% of the shares underlying the related Note, rounded to the nearest whole share.
  5. F5. On May 29, 2026, the Issuer amended all outstanding Notes and Warrants issued in the private placement, on the same terms for all holders, to reduce the conversion price of the Notes from $5.00 to $3.00 per share, to reduce the exercise price of the Warrants from $7.50 to $4.50 per share, and to increase the number of shares issuable under each Warrant to maintain 100% coverage of the shares underlying the related Note (for the reporting person, from 10,000 to 16,667 shares). No additional consideration was paid. The amendment was approved by the Issuer's Board of Directors and is reported as the deemed cancellation of the original Note and Warrant and the acquisition of the amended Note and Warrant, exempt under Rule 16b-3(e) and Rule 16b-3(d), respectively
March note principal $50,000 Note acquired March 11, 2026; reported by principal amount.
March note underlying common shares 10,000 shares Underlying shares reported for the note acquired March 11, 2026.
Note conversion price Changed from $5.00 to $3.00 per share May 29, 2026 amendment.
Warrant exercise price Changed from $7.50 to $4.50 per share May 29, 2026 amendment.
Shares issuable under warrant Increased from 10,000 to 16,667 shares May 29, 2026 amendment for James Pawloski’s warrant.
November note principal $25,000 Note acquired November 2, 2026; reported by principal amount.
November warrant shares 8,333 shares Warrant acquired November 2, 2026.
Deferred interest added to March note principal $2,780.82 Added September 30, 2026; excluded from the principal and underlying-share figures reported.
10% Secured Convertible Notes financial
"acquired the Issuer's 10% Secured Convertible Notes"
private placement financial
"from the Issuer in a private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
principal amount financial
"The Notes are reported by principal amount"
The principal amount is the original sum of money that is borrowed, lent, or invested before any interest, fees, or returns are added. It matters to investors because interest charges, scheduled repayments, and total return are calculated from that base amount — think of it as the price tag on which future costs or gains are built. Knowing the principal helps you compare deals and predict cash flows and risk.
deferred interest financial
"of deferred interest was added to the principal amount"
Deferred interest is a credit arrangement where interest on a purchase is postponed during a promotional period; if the borrower pays off the balance within that time no interest is charged, but if they miss the deadline the accumulated interest is billed retroactively. For investors this matters because it affects a company’s actual cash flow and credit losses—like a store offering a ‘pay later’ trial, it can boost short-term sales but raises the risk of larger unexpected write-offs if many customers fail to pay.
third scheduled trading day technical
"third scheduled trading day preceding the maturity date"
deemed cancellation technical
"reported as the deemed cancellation of the original Note"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did James Pawloski acquire from 374Water (SCWO) on November 2, 2026?

James Pawloski acquired a 10% secured convertible note reported at $25,000 principal and a warrant for 8,333 common shares. The note was purchased at 100% of principal; the warrant was issued with it for no separate consideration. The note’s conversion price is $3.00 per share and the warrant’s exercise price is $4.50 per share.

What changed in the 374Water (SCWO) note and warrant amendment on May 29, 2026?

The note conversion price changed from $5.00 to $3.00 per share, and the warrant exercise price changed from $7.50 to $4.50 per share. The number of shares issuable under the reporting person’s warrant increased from 10,000 to 16,667. The original instruments were reported as canceled and the amended instruments acquired, with no additional consideration paid.

What are the conversion and interest terms of 374Water (SCWO) Notes?

The Notes bear 10% interest per annum and may be converted at the holder’s option before the close of business on the third scheduled trading day preceding maturity. Accrued and unpaid interest is also convertible at the conversion price. Related Warrants are exercisable for cash only, beginning on issuance and expiring three years thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pawloski James

(Last)(First)(Middle)
C/O 374WATER INC
100 SOUTHCENTER COURT SUITE 200

(Street)
MORRISVILLE NORTH CAROLINA 27560

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
374Water Inc. [ SCWO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
10% Secured Convertible Note$503/11/2026A50,000(1)03/11/202603/11/2029Common Stock10,000$50,000(2)50,000D
Warrant (right to buy)$7.503/11/2026A10,000(4)03/11/202603/11/2029Common Stock10,000$0(2)10,000D
10% Secured Convertible Note$505/29/2026D50,000(5)03/11/202603/11/2029(3)Common Stock10,000(5)0D
10% Secured Convertible Note$305/29/2026A50,000(5)05/29/202603/11/2029(3)Common Stock16,667(5)50,000D
Warrant (right to buy)$7.505/29/2026D10,000(5)03/11/202603/11/2029Common Stock10,000(5)0D
Warrant (right to buy)$4.505/29/2026A16,667(5)05/29/202603/11/2029Common Stock16,667(5)16,667D
10% Secured Convertible Note$311/02/2026A25,000(1)11/02/202611/02/2029(3)Common Stock8,333$25,000(2)25,000D
Warrant (right to buy)$4.511/02/2026A8,333(4)11/02/202611/02/2029Common Stock8,333$0(2)8,333D
Explanation of Responses:
1. The reporting person acquired the Issuer's 10% Secured Convertible Notes (the "Notes") and the related common stock purchase warrants (the "Warrants") from the Issuer in a private placement. The reporting person's participation was approved in advance by the Issuer's Board of Directors, and the acquisition is exempt under Rule 16b-3(d). The Notes are reported by principal amount.
2. The Notes were purchased at 100% of their principal amount. The Warrants were issued together with the Notes for no separate consideration.
3. The Notes bear interest at 10% per annum and are convertible, at the holder's option, into common stock at any time before the close of business on the third scheduled trading day preceding the maturity date, which is three years from the date of issuance. The number of underlying shares is the principal amount divided by the conversion price, rounded to the nearest whole share, and excludes accrued and unpaid interest, which is also convertible at the conversion price. On September 30, 2026, $2,780.82 of deferred interest was added to the principal amount of the Note issued on March 11, 2026; that amount is not included in the principal amount or underlying shares reported above.
4. The Warrants are exercisable for cash only, beginning on the date of issuance and expiring three years thereafter. The number of Warrant shares equals 100% of the shares underlying the related Note, rounded to the nearest whole share.
5. On May 29, 2026, the Issuer amended all outstanding Notes and Warrants issued in the private placement, on the same terms for all holders, to reduce the conversion price of the Notes from $5.00 to $3.00 per share, to reduce the exercise price of the Warrants from $7.50 to $4.50 per share, and to increase the number of shares issuable under each Warrant to maintain 100% coverage of the shares underlying the related Note (for the reporting person, from 10,000 to 16,667 shares). No additional consideration was paid. The amendment was approved by the Issuer's Board of Directors and is reported as the deemed cancellation of the original Note and Warrant and the acquisition of the amended Note and Warrant, exempt under Rule 16b-3(e) and Rule 16b-3(d), respectively
/s/ James Pawloski11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading